- ICH GCP
- EU: n kliinisten tutkimusten rekisteri
Viimeisimmät kokeilut
EudraCT Number: 2004-001452-36 | Sponsor Protocol Number: XM02-02-INT | Start Date: 2004-06-30 | ||||||
Sponsor Name: BioGeneriX | ||||||||
Full Title: Efficacy and Safety of XM 02 compared to Filgrastim in patients with breast cancer receiving chemotherapy. Multinational, multicentre, randomised, controlled study | ||||||||
Medical condition: Patients with breast cancer high risk stage II or stage III/IV (classification according to American Joint Committee on Cancer [AJCC] receiving chemotherapy and developing Neutropenia due to chemot... | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: HU (Completed) LT (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000996-16 | Sponsor Protocol Number: 694/30.06.04 | Start Date: 2004-06-30 | |||||||||||
Sponsor Name: AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I | |||||||||||||
Full Title: Silence Study - Longitudinal study on the use of aspirin versus placebo in patients with silent cerebral infarcts | |||||||||||||
Medical condition: prevention of occlusive ischemic events in patient with transient ischemic attacs or after brain infarct, | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000767-10 | Sponsor Protocol Number: V82P1 | Start Date: 2004-06-29 | |||||||||||
Sponsor Name: CHIRON | |||||||||||||
Full Title: A Phase I/II, Single Center, Partially Observer-Blind, Controlled, Randomized Study to Explore Safety and Immunogenicity in Healthy Adult Subjects who Receive Either One Dose of Chiron Combined Men... | |||||||||||||
Medical condition: Active immnunisation for the prevention of invasive disease caused by N. Meningitidis serogroup C and H. influenzae type b | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000609-23 | Sponsor Protocol Number: BXL-6280213 | Start Date: 2004-06-25 | |||||||||||
Sponsor Name: BIOXELL SPA | |||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel-group study to determine the effect of BXL-628 in post-menopausal women with Overactive Bladder (OAB) | |||||||||||||
Medical condition: overactive bladder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000206-31 | Sponsor Protocol Number: C1 1304-01 | Start Date: 2004-06-22 | |||||||||||
Sponsor Name: PHARMING TECHNOLOGIES B.V. | |||||||||||||
Full Title: A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema | |||||||||||||
Medical condition: hereditary angioedema (HAE) treatment | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001301-10 | Sponsor Protocol Number: EOP1009 | Start Date: 2004-06-14 | |||||||||||
Sponsor Name: PFIZER | |||||||||||||
Full Title: A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED, DOSE-RANGING, MULTI-CENTER TRIAL TO ASSESS THE EFFECT OF PEGAPTANIB SODIUM ON FOVEAL THICKENING IN PATIENTS WITH EXUDATIVE SUBFOV... | |||||||||||||
Medical condition: AGE-RELATED MACULAR DEGENERATION | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000603-18 | Sponsor Protocol Number: Q10DOWN | Start Date: 2004-06-11 | ||||||
Sponsor Name: AZIENDA OSPEDALIERA UMBERTO I | ||||||||
Full Title: ubiquinone in Down syndrome | ||||||||
Medical condition: Down syndrome | ||||||||
|
||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: IT (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000507-17 | Sponsor Protocol Number: SC1-04 | Start Date: 2004-06-10 | ||||||
Sponsor Name: FONDAZIONE SANTA LUCIA | ||||||||
Full Title: Effectiveness of rivastigmine treatment in post-stroke patients with right brain damage and unilateral spatial neglect | ||||||||
Medical condition: Improvement of unilateral spatial neglect and functional status in right brain damaged patients | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: IT (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000782-35 | Sponsor Protocol Number: CERL080AIT06 | Start Date: 2004-06-10 | |||||||||||
Sponsor Name: NOVARTIS FARMA | |||||||||||||
Full Title: EVALUATION OF THE QUALITY OF LIFE AND GASTROINTESTINAL SYMPTOMS AFTER CONVERSION TO MYFORTIC (ERL080) and CELLCEPT WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS TREATED WITH TACROLIMUS. | |||||||||||||
Medical condition: Prophylaxis of transplant rejection in adult patients receiving calcineurin inhibitors with / without corticosteroids after allogeneic renal transplants. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000374-31 | Sponsor Protocol Number: SB-683699/003 | Start Date: 2004-06-09 | ||||||
Sponsor Name: GLAXO SMITHKLINE | ||||||||
Full Title: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-Ranging Study to Investigate the Efficacy and Safety of Three Months administration of SB 683699 (150 - 1200mg twice daily) in ... | ||||||||
Medical condition: Relapsing Multiple Sclerosis | ||||||||
|
||||||||
Population Age: Adults | Gender: Male, Female | |||||||
Trial protocol: IT (Completed) | ||||||||
Trial results: View results |